Availability and Patterns of Intravesical BCG Instillations

Slawomir Poletajew, Aleksandra Majek, Piotr Magusiak, Katarzyna Sledzikowska, Bartosz Dybowski, Piotr Radziszewski



Purpose: Intravesical BCG instillations improve recurrence free survival in patients with non-muscle-invasive bladder cancer (NMIBC).
Methods: This is a national survey study, covering 223 urological centres, aimed at reliable identification of BCG availability and implemented treatment patterns.
Results: Response rate was 93.7%. BCG was used in 56.5% of urological departments. Another 22.7% referred patients to other hospitals for instillations, while 20.8% did not recommend BCG at all. The most common indications for BCG instillations were as follows: T1 tumours (88.5%), carcinoma in situ (83.6%) and high grade tumours (73.8%). Maintenance therapy was routinely abandoned in 16.4% of centres or was scheduled for <1 year, 1 year, 3 years and 1-3 years in 6.6%, 19.7%, 21.3% and 31.2% of centres, respectively. Continuation of BCG
despite treatment failure in carcinoma in situ cases was considered in 21.3% of departments.
Conclusion: Our findings indicate that BCG is underused, while patterns of maintenance and follow-up are suboptimal.

Full Text:




Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R. Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? Urol Int.


Aziz A. BP, Chun FK, Dobruch J, et al. Discrepancy between guidelines and daily practice in the management of non-muscleinvasive bladder cancer (NMIBC): Results of a European survey. Eur Urol Suppl. 2016;15:e216.

Dybowski B, Ossolinski K, Ossolinska A, Peller M, Bres-Niewada E, Radziszewski P. Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. Cent European J Urol. 2015;68:278-83.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

Poletajew S, Biernacki R, Buraczynski P, et al. Stage of bladder cancer in Central Europe -Polish perspective. Neoplasma. 2016;63:642-7

Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69-76.

Oddens JR, Sylvester RJ, Brausi MA, et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014;66:694-701.

Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013;112:742-50.

Nielsen ME, Smith AB, Pruthi RS, et al. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int. 2012;110:967-72.

Gontero P, Oderda M, Altieri V, et al. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study. Urol Int. 2011;86:19-24.

Chamie K, Saigal CS, Lai J, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117:5392-401.

DOI: http://dx.doi.org/10.22037/uj.v14i6.3781

Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License